

Model based development of tacrolimus dosing algorithm considering CYP3A5 genotypes and mycophenolate mofetil drug interaction in stable kidney transplant recipients

Jae Hyun Kim Ph.D.¹, Nayoung Han Ph.D.¹, Myeong Gyu Kim Ph.D.^{1,2}, Young Won Kim M.S.¹, Hayoung Jang B.S.¹, Hwi-Yeol Yun Ph.D.³, Mi-Yeon Yu M.D.⁴, In-Wha Kim Ph.D.¹, Yon Su Kim M.D., Ph.D.^{5,6*} and Jung Mi Oh Pharm.D.^{1*}

¹College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea

²Graduate School of Clinical Pharmacy, CHA University, Republic of Korea

³College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea

⁴Department of Internal Medicine, Hanyang University Guri Hospital, Guri, Republic of Korea

⁵Kidney Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea

⁶Department of Medical Science, Seoul National University College of Medicine, Seoul, Republic of Korea

***Co-corresponding Authors**

Yon Su Kim M.D., Ph.D.


Department of Medical Science, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea.

Kidney Research Institute, Seoul National University College of Medicine
101 Daehak-ro, Jongno-gu, Seoul 03080, Korea

Tel.: +82 2 2072 2264; fax: +82 2 745 2264; email address: yonsukim@snu.ac.kr


Jung Mi Oh Pharm.D., College of Pharmacy, Research Institute of Pharmaceutical Sciences,
Seoul National University, 1 Gwanakro, Gwanak-gu, Seoul 08826, Korea. Tel.: +82 2 880
7736; fax: +82 2 882 9560; email address: jmoh@snu.ac.kr

Figure legend




Supplementary Figure S1 Goodness-of-fit plot of tacrolimus for the population


pharmacokinetic model. (a) population prediction (PRED) vs. observed concentration (DV); (b) individual prediction (IPRED) vs. DV; (c) conditional weighted residuals (CWRES) vs. TIME; (d) CWRES vs. PRED.



Supplementary Figure S2 Goodness-of-fit plot of mycophenolic acid for the population pharmacokinetic model. (a) population prediction (PRED) vs. observed concentration (DV); (b) individual prediction (IPRED) vs. DV; (c) conditional weighted residuals (CWRES) vs. TIME; (d) CWRES vs. PRED.



Supplementary Figure S3 Goodness-of-fit plot of mycophenolic acid 7-O-glucuronide for the population pharmacokinetic model. (a) population prediction (PRED) vs. observed concentration (DV); (b) individual prediction (IPRED) vs. DV; (c) conditional weighted residuals (CWRES) vs. TIME; (d) CWRES vs. PRED.



Supplementary Figure S4 Goodness-of-fit plot of mycophenolic acid acyl glucuronide for the population pharmacokinetic model. (a) population prediction (PRED) vs. observed concentration (DV); (b) individual prediction (IPRED) vs. DV; (c) conditional weighted residuals (CWRES) vs. TIME; (d) CWRES vs. PRED.